In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome

Journal of Infectious Diseases

Volumn 178, Issue 6, 1998, Pages 1821-1825

  Cherrington, J M ^a   Fuller, M D ^b   Lamy, P D ^b   Miner, R ^b   Lalezari, J P ^b   Nuessle, S ^b   Drew, W L ^b  

^a GILEAD SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG SENSITIVITY; HUMAN; PRIORITY JOURNAL; RETINITIS; TREATMENT OUTCOME; VIRUS ISOLATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; DRUG RESISTANCE, MICROBIAL; FOSCARNET; GANCICLOVIR; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RECURRENCE;

EID: 0031768274     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314487     Document Type: Article

References (15)

1. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemo 1997;8:1-23.
2. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Med Virol 1997;7:145-56.
3. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349:1443-5.
4. Crumpacker CS. Drug resistance in Cytomegalovirus: current knowledge and implications for patient management. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(suppl 1).
5. Field AK, Biron KK. "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev 1994;7:1-13.
6. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997;176:69-77.
7. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
8. Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow-replication phenotype in cell culture. Virology 1998;248:382-93.
9. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998;72:5927-36.
10. Smith IL, Flores-Aguilar M, Taskituna I, Jiles RE, Freeman WR, Spector SA. Cytomegalovirus resistance is associated with clinical failure in AIDS patients receiving ganciclovir treatment for retinitis [abstract H30]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996.
11. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J Infect Dis 1997;176:50-8.
12. Cherrington JM, Miner R, Hitchcock MJM, Lalezari JP, Drew WL. Susceptibility of human cytomegalovirus (HCM V) to cidofovir is unchanged after limited in vivo exposure to various clinical regimens of drug. J Infect Dis 1996;173:987-92.
13. Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997;176:786-9.
14. Kouzarides T, Bankier AT, Satchwel SC, Weston K, Tomlinson P, Barrell BG. Sequence and transcription analysis of the human cytomegalovirus DNA polymerase gene. J Virol 1987;61:125-33.
15. Erice A, Gil-Roda C, Pérez J, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175:1087-92.